MYC Gene Amplification Frequently Observed in Stomach and Gastroesophageal Junction Cancers, Associated with Male Gender and Diminished Neoadjuvant Treatment Efficacy - Top-Institutions - MDSpire

MYC Gene Amplification Frequently Observed in Stomach and Gastroesophageal Junction Cancers, Associated with Male Gender and Diminished Neoadjuvant Treatment Efficacy

  • By

  • Ole Biegler

  • Hans-Michael Behrens

  • Jochen Haag

  • Thomas Becker

  • Steffen Markus Heckl

  • Silke Lüschen

  • Christoph Röcken

  • April 24, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Gastrointestinal Oncology
    • Molecular Oncology
    • Cancer Genomics

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Gastrointestinal Oncology
    • Cancer Genomics
    • Translational Research

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Gastrointestinal Oncology
    • Molecular Pathology
    • Clinical Trials

  • #4

    German Cancer Research Center (DKFZ)
    German Cancer Research Center (DKFZ)

    Heidelberg, Baden-Württemberg

    Key Differentiators

    • Cancer Genomics
    • Molecular Oncology
    • Gastrointestinal Cancer Research

  • #5

    National Cancer Center Hospital
    National Cancer Center Hospital

    Tokyo, Tokyo

    Key Differentiators

    • Gastrointestinal Oncology
    • Molecular Oncology
    • Clinical Research

Original Source(s)

MYC Gene Amplification Frequently Observed in Stomach and Gastroesophageal Junction Cancers, Associated with Male Gender and Diminished Neoadjuvant Treatment Efficacy

  • by Ole Biegler, Hans-Michael Behrens, Jochen Haag, Thomas Becker, Steffen Markus Heckl, Silke Lüschen, Christoph Röcken

  • April 24, 2026

Related Content

Biotech exec Jeremy Levin on the industry’s strategic turning point

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation